The IAEA and St. Jude Children’s Research Hospital have begun to develop new training curricula to upscale global capacity in paediatric cancer care by helping to close knowledge gaps around the world ...

Financial success will permit smart monetary investments today. There is no scope for debates and clashes in the relationship ...

Scientists have discovered more than 140 medications that alter the gut microbiome, forcing bacteria to compete for nutrients ...

Since the development of immune checkpoint inhibitors, very few advances have been made in the field of solid oncology therapeutics. This is due to the ...

OBI-902, targeting TROP2, gains FDA orphan drug status for cholangiocarcinoma, a rare cancer with poor prognosis and limited treatments. Orphan drug designation provides benefits like tax credits and ...

The Princess of Wales stopped by the Future Workforce Summit in London to discuss her Royal Foundation’s Business Taskforce ...

The company, which had no revenue last year and $5.1 million in sales for the first nine months of this year with widening ...

Aggressive cancer cells are masters of movement. When they spread through the body, they cause metastasis, which significantly reduces a person's chance of survival. For this spreading to take place, ...

Discover the emergence of dual-payload ADCs and PDCs, which could mark a significant evolution in targeted therapeutics.

Only one clinical-stage asset from the ProfoundBio acquisition remains in development: The antibody-drug conjugate Rina-S, in ...

With positive data from the Phase III HERIZON-GEA-01 study, Zymeworks and Jazz Pharmaceuticals will file an approval ...

Having found swift success with its Jazz Pharmaceuticals and BeOne Medicines-licensed cancer med Ziihera, Zymeworks has ...